SLE
50
11
15
14
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.0%
3 terminated out of 50 trials
82.4%
-4.2% vs benchmark
6%
3 trials in Phase 3/4
29%
4 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (50)
JBT-101 in Systemic Lupus Erythematosus (SLE)
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
A Study of RD06-04 in Patients With Active Autoimmune Diseases
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus
Pregnancies Before the Diagnosis of Systemic Lupus Erythematosus
Myocardial Inflammation in Systemic Lupus Erythematosus
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
Safety and Efficacy of ONT01 in Lupus
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
Association of Serum Interleukin-33 Levels With Clinical Manifestations in Systemic Lupus Erythematosus
SLE Severity Linked to Vitamin D Via Treg Cells in Pediatric Patients
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases
Improving the Assessment of SLE Disease Activity